MedTrace Logo

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

NCT05349045 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-04-27

No results posted yet for this study

Summary

The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.

Conditions

  • Esophageal Neoplasms

Interventions

DRUG

an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor

This is an observational study

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-05
Primary Completion
2024-05-05
Completion
2025-05-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349045 on ClinicalTrials.gov